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Modified plasma clearance technique using nonradioactive
iothalamate for measuring GFR
YOSHITAKA ISAKA, Y0sHIHIR0 FuJIwA1&, SHIGEO YAMAMOTO, SATOSHI OcHI,
SUNGHYO SHIN, TORU INOUE, KuNlo TAGAWA, TAKENOBU KAMADA, and NAOHIKO UEDA
1st Department of Medicine, Osaka University Medical School, and Department of Physiological Chemistry, Medical School, Osaka
University, Osaka, Japan
Glomerular filtration rate (GFR) is believed to be the overall
index of renal function in health and disease. And the renal
clearance of inulin (C1) obtained during constant intravenous
infusion has long been accepted as the gold standard of GFR
measurement. Because of a number of technical difficulties
inherent in the assay of inulin concentration in urine and
plasma, its usefulness in clinical practice is limited.
lothalamate, a urographic contrast medium which behaves
and is excreted in a fashion similar to inulin, has been accepted
as a good filtration marker [1—31. The renal clearance of
iothalamate is not much more simplified than that of inulin. But
its measurement is used instead of inulin in the assessment of
GFR.
Whether inulin or iothalamate is used, the measurement of
renal clearance requires proper collection and measurement of
an accurate short-timed urine specimen. Therefore improper
urine collection sometimes leads to error in GFR measurement.
To overcome this disadvantage, GFR is alternatively deter-
mined as the total plasma clearances calculated from serial
measurement of plasma concentrations after a single rapid
intravenous injection, where urine collection is not necessary
[4, 51. The total plasma clearance should be equal to glomerular
filtration rate, if the compounds would be excreted solely by
glomerular filtration without tubular secretion or reabsorption.
The conventional method of the total plasma clearances, how-
ever, usually needs multiple blood samples to calculate from the
slope of the plasma disappearance curve, The plasma disap-
pearance curve is generally separated into two compartments:
the early phase reflects the distribution of the marker and the
late phase reflects the excretion of the marker. The latter is
closely related with the clearance rate [6]. So, the late phase of
the plasma disappearance curve would offer a simple and good
approximation of GFR, and it would conquer the disadvantages
of the renal clearances and total plasma clearances, that is,
timed urine collections and multiple blood sampling, respec-
tively.
The aim of this investigation was to study whether GFR could
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be estimated by the modified plasma clearance technique to
calculate only from the late phase of the plasma decline at 60,
90, and 120 minutes, without urine collection, when iothalamate
was used as filtration marker and high-performance liquid
chromatography (HPLC) system as the analyzing method.
Methods
Subjects
Twenty-four patients, seventeen male and seven female, aged
17 to 72 years (median 47 years), weighing 47 to 80 kg (median
62 kg) with chronic renal disease and wide range of renal
function (inulin clearance: C1 10 to 130 mI/mm), and three
healthy male volunteers, aged 31 to 34 years (median 32 years),
weighing 60 to 67 kg (median 63 kg) were studied. The clinical
diagnoses of patients were chronic glomerulonephritis (21),
diabetic nephropathy (2), and polycystic kidney disease (1).
Three patients had moderate edema due to nephrotic syndrome.
None had lower urinary tract obstruction. All studies were
performed in Osaka University Hospital. Subjects with a his-
tory of allergy to iodine were excluded from entry. Informed
consent was obtained from all patients and volunteers.
Protocol
After an overnight fast, subjects were given orally 300 ml of
water before the study. Subjects rested supine, but were
allowed to stand up during voiding. A polyethylene catheter
was inserted into a cubital vein in both arms. Depending on
GFR and the body weight, a 25% inulin solution was continu-
ously infused from t = —45 minutes. In eight patients, a 20%
para-aminohippuric acid (PAH) solution was simultaneously
infused. At t = 0 mm, 1 ml of a 30% iothalamate (Conray®) was
injected and the catheter was flushed through with 5 ml of a
0.9% NaCI solution. Blood samples were drawn from the
opposite arm at 10, 30, 60, 90 and 120 minutes. In only one
healthy volunteer, blood samples were drawn at 2, 5, 10, 20, 30,
60, 90 and 120 minutes. At t = 15 minutes, subjects voided and
clearance timing began. Four 30-minute clearance periods were
then performed. Urine samples were collected by voluntary
voiding.
lothalamate and PAH were determined by HPLC system
which consisted of Shimadzu LC-6A liquid chromatograph,
Shimadzu SPD-6A UV spectrophotometric detector (Shimadzu
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Co., Kyoto, Japan) and reverse-phase column YMC-Pack A312
S-5 (6 mm x 150 mm; Yamamura Chemical Laboratories Co.,
Kyoto, Japan). The mobile phase consisted of methanol and 0.1
mol/liter NaH2PO4 (15:85, vol/vol). The flow rate was 1.0
mi/mm. Samples were quantified by UV absorption at 245 nm
relative to a standard curve. Serum samples were precipitated
with four volume of 0.64 mol/liter perchloric acid and centri-
fuged. Urine samples were diluted 20 times with deionized
water prior to addition of perchloric acid. An aliquot of the
supernatant (5 d) was subsequently injected onto the column.
The concentration of inulin was measured by anthrone
method [7]. The concentration of creatinine in serum and urine
was measured by the alkaline picrate colorimetric method [8].
PAH was measured by colorimetric method, too [9].
Calculations
The renal clearances of inulin, creatinine, and iothalamate
were calculated using the standard formula: C = UV/P, in
which V is the urine volume per minute, and U and P are the
urine and plasma concentrations. And the average of four
30-minute clearance periods was regarded as the renal clear-
ance of the subject.
The decline of the plasma level after an intravenous injection
of iothalamate could divide into two phases and the feasibility
of using a two-compartment model to describe the elimination
of iothalamate was investigated by using the following formula:
Cp = Ae + Be_$t
where Cp is the plasma concentration; a,/3, the hybrid rate
constant; A,B, the zero-time intercept; and t is time.
The first phase (a) includes the distribution of drug from the
central compartment, such as the intravascular space, into the
second compartment, such as the extravascular space. After a
certain time, the graph moves into a log/linear phase (/3) (Fig.
la). This log/linear phase (/3) represents elimination from the
central compartment. The hybrid rate constant, /3, and the
clearance rate constant are closely related. The elimination of
iothalamate is considered to take place only from the central
compartment. Therefore, the rate of elimination at equilibrium
is governed by the amount of iothalamate in the central com-
partment, and the clearance is calculated from the slope of the
linear terminal part (/3).
The hybrid rate constant, /3, and the zero-time intercept, B,
were calculated from the slope of late decline at three time
points (60, 90 and 120 mm) by using the following formula:
Log10Cp = B — /3t (Fig. ib)
The modified plasma clearances of iothalamate (C10-M) were
calculated using the following formula:
D x /3 x log10
Ci0-M = ____________
1.34
where D is the initial amount of iothalamate; 1.34 is the
correlation factor, approximately calculated from the intravas-
cular space and distribution volume [10].
Results
Representative chromatograms of serum and urine samples are
shown in Figure 2. lothalamate was eluted as a single peak at
6.0 minutes, and no interfering peaks were observed in the
serum and urine sample blanks. The assay was liner within the
wide range of concentrations of iothalamate (1 to 100 mg/liter).
And the coefficient of variation of repeated measures of iothala-
mate was 2.1%. In our HPLC system, para-aminohippuric acid
(PAH) could be simultaneously determined (retention time: 4.0
mm). The detection limit for PAH was approximately from 1
mg/liter to 100 mg/liter. The PAH values obtained by our HPLC
method were well consistent with those obtained by the p-di-
methylaminocinnamaldehide colorimetric method of Yatzidis
[9]. The difference between the values obtained by the two
independent methods was within 2.5%.
The renal clearances were determined in 23 subjects, because
one subject could not void punctually. The renal clearances of
creatinine and iothalamate (Car, C10) were compared with that
of inulin. The slopes with zero intercept of Cr versus C1 and
C10 versus C1 were 1.23 0.01 (r = 0.99) and 1.05 0.01 (r =
0.98), respectively.
The serial plasma concentrations of iothalamate in one
healthy volunteer after an intravenous injection are shown in
Figure lc. This plasma disappearance curve was similar to the
graph of the two compartment model, shown in Figure la. From
t = 60 minutes the graph moved into a log/linear phase. The
modified plasma clearance of iothalamate compared with the
renal clearances of iothalamate and inulin are shown in Figure
3. The slopes with zero intercept of C10-M versus C10, and
C10-M versus C1 were 0.99 0.01 (r = 0.98) and 1.05 0.01
(r = 0.99), respectively.
In this study side effects including nausea, vomiting, and
urticaria were not observed.
Discussion
In the present study, we employed a new method, modified
plasma clearance, to determine glomerular filtration rate. This
method employed non-radioactive iothalamate and required no
constant infusion, timed urine collection, nor multiple blood
sampling. The concentration of iothalamate was easy and
accurate to measure by using HPLC.
Radioactive iothalamate has become universally accepted as
an accurate marker for determining GFR [1—3]. But the use of
radioisotopes requires complicated handling of storage and
disposal of contaminated waste, and has an additional disad-
vantage of radiation exposure of the bladder wall and gonads,
and a risk of uptake by thyroid gland by the patient. A sterile,
pyrogen-free aqueous preparation of radioactive iothalamate is
not necessarily available except for the United States. Re-
cently, analytical methods for measuring iothalamate by HPLC
have been developed [10, 11]. However, we developed a new
analytical method for measurement of iothalamate. This
method offers the additional advantage of being able to simul-
taneously measure PAH. Some colorimetric procedures of
PAH assay may be positive for a variety of para-amino aromatic
compounds, whereas our HPLC assay was linear within wide
range of concentrations of PAH, and no interference was found
in plasma and urine. So, our HPLC method seems to have a
greater advantage than colorimetric assays, especially in high
I I I
30 60 90
concentrations of PAH. Therefore, in the same biological
samples and the same HPLC system, one would be able to
determine the clearance of iothalamate and PAH, that is, GFR
and renal plasma flow, simultaneously. In our HPLC method a
small sample volume with deproteinization is needed. The
retention time of iothalamate was 6.0 minutes, and the coeffi-
cient of variation was 2.1%. We could rapidly and accurately
determine iothalamate.
In agreement with earlier studies [1—3, 121, the renal clear-
ance of iothalamate was correlated well with that of inulin
determined simultaneously (C10/C1 1.05 0.01, r = 0.98),
whereas the renal clearance of creatinine was significantly
Fig. 1. A. The plasma concentrations after an intravenous injection in
the two compartment model. A semi-logarithmic plot is shown. The
experimental points lie on the solid line. B. After a certain time the
graph moves into a log/liner phase. This phase represents eliminationj from the central compartment. The slope of line is described by
Log10Cp = B — f3t, where Cp is plasma concentration and t is time after
120 injection. C. The plasma concentrations after an intravenous injection
of iothalamate in healthy volunteer are shown. The plasma level decline
is considered to be approximate to the two compartment model.
higher than that of inulin (CCJCIfl 1.23 0.01, r = 0.99). In
the study by Odlind et al, iothalamate was not a suitable marker
for glomerular filtration because of its tubular secretion [131. It
is a weak acid and may presumably be a subject for active
secretion; however, from our clearance data, the gain of
iothalamate clearance with a minute dose was not significant.
Therefore lothalamate is considered to be an appropriate
marker for glomerular filtration rate, as far as the minute dose of
iothalamate is used.
We found an excellent agreement between the modified
plasma clearance and the renal clearance of iothalamate (C10-
M/CSO = 0.99 0.01, r 0.98). We also found a close
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Fig. 2. Chromatogranis of (A) serum and (B)
urine samples containing iothalamate (25 ingI
liter and 150 ,ng/liter, respectively) and PAN
(4 mgldl and 80 mg/dl, respectively).
correlation between the modified plasma clearance of iothala-
mate and the renal clearance of inulin (C10-M/C1 = 1.05
0.01, r = 0.99). The decline of the serial plasma concentrations
after intravenous injection of iothalamate was considered to be
in good approximation to the ideal decline in the two compart-
ment model. We used the time at 60, 90, and 120 minutes after
injection to be the sampling time of choice, because the
elimination curve of iothalamate was log/linear around this
time, as shown in Figure ic.
The routine method for determination of total plasma clear-
ance usually utilizes multiple blood samples. But the late phase
of the plasma disappearance curve after single injection of
iothalamate is closely related with GFR [6]. The modified
plasma clearance is calculated theoretically only from three
blood samples. We needed the correlation factor to determine
GFR by the modified plasma clearance technique. If lothala-
mate should be distributed into the central compartment, in this
case the plasma, and be rapidly equilibrated with the second
compartment, in this case the tissue, the elimination rate of
iothalamate will be determined by not only the glomerular
filtration but also the ratio between the central and the second
compartment. Therefore in the equilibrium phase, in this case
the late phase of the plasma disappearance curve, GFR should
be determined by the plasma elimination rate of lothalamate and
the correlation factor, which is calculated from the intravascu-
lar space and distribution volume. This correlation factor was
the same in all patients despite a wide range of renal function,
but our study nevertheless showed an excellent agreement
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Fig. 3. The mod(fied plasma clearance calculated only from the late phase of the plasma decline at 60, 90, 120 minutes after an intravenous
injection of iothalamate are compared with the renal clearances of iothalamate (A) and maIm (B). The line of identity is also drawn (0: subject
without edema •: subjects with edema).
between the modified plasma clearance of iothalamate and the
renal clearance of inulin irrespective of renal function. There-
fore, in assessment of GFR, this correlation factor, 1.34, and a
new method, the modified plasma clearance technique, would
be available regardless of renal function.
Prescott, Freestone and McAuslane reported the single injec-
tion and total plasma clearance of inulin [14], but it seems to us
that inulin is unsuitable for single injection technique, because
of the large dose of inulin given over five minutes. In previous
reports the total plasma clearance of inulin or 51Cr-ethylenedi-
aminetetraacetate exceeded the simultaneously measured renal
clearance [5, 14]. As compared with the total plasma clearance,
the modified plasma clearance technique does not need multiple
blood sampling, for example, initial frequent sampling nor delay
sampling (4 to 6 hours after injection). In addition, this tech-
nique, which does not need urine collection, will have a great
advantage in patients with difficulties in urination, for example,
in those with a neurogenic bladder or urinary tract obstruction.
Experimental studies utilizing the single-injection and modi-
fied plasma clearance technique will therefore have more ad-
vantage in the measurement of GFR than those utilizing the
classical constant infusion technique with urine collection.
Although the correlation factor is approximately estimated
from the intravascular and extravascular volume, the modified
plasma clearance technique was found to be effective under
different conditions, for example, edema and polycystic kidney
disease. It is probably because the distribution of contrast
media into the third space, such as edema and cyst, can be
disregarded. The results were not different with sexes. So this
technique seems to be valid without distinction of sex or
disease.
In conclusion, the present study has shown excellent corre-
lation of the modified plasma clearance of iothalamate with the
renal clearance of inulin and iothalamate in patients and normal
volunteers with wide range of renal function. This justifies the
use of the single injection and modified plasma clearance
technique in the measurement of GFR. The modified plasma
clearance technique can avoid errors in urine collection and
pain of multiple blood sampling. Therefore, the single injection
and modified plasma clearance technique is suitable for routine
measurement of GFR.
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